Breakpoints

In this discussion, experts Chuck Peloquin, a TB treatment guideline contributor from the University of Florida, and Gerry Davies, an infection pharmacology professor at the University of Liverpool, delve into the complexities of rifampin dosing. They debate whether higher doses improve outcomes and explore toxicity thresholds. The duo also discusses alternative rifamycins and management strategies for patients with complications. Tune in for insights on optimizing treatment through therapeutic drug monitoring, especially for those with concurrent infections.

Drs. Jim Rhodes and Molly Steed join host Jeannette Bouchard to discuss all things related to optimal dosing of daptomycin. This podcast episode provides insight on why dosing matters with this antibiotic, especially with certain organisms (looking at you, E. faecium), why weight matters with dosing, and what that pesky CPK means. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/  References: Fixed-dose daptomycin in Staphylococcus aureus: doi 10.1002/phar.4602 High dose daptomycin for VRE: doi 10.1093/cid/ciw815 This podcast is powered by Pinecast.

In this engaging discussion, Dr. Erica Stohs, an infectious diseases physician and policy advisor, Dr. Ryan Stevens, a pharmacist specializing in antimicrobial stewardship, and Jayme McRae, a clinical pharmacology consultant, dive into the nuances of antibiotic stewardship. They share best practices for managing outpatient antibiotic use, the importance of clear communication during patient transitions, and innovative strategies like the 'viral RX pad.' The trio also addresses challenges like diagnosing infections in elderly patients and the role of pharmacists in enhancing care.

Join Prof Jason Roberts and Dr. Erin McCreary for this episode dedicated to discussing the results of the BLING III trial, which explored the use of continuous versus intermittent infusion of a beta-lactam antibiotic in critically ill patients. Reference: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. 10.1001/jama.2024.9779

Drs. Jeffrey Pearson and Jason Pogue join Dr. Jeannette Bouchard as they take on all things tetracyclines. Starting with tetracycline, they walk through differences between each generation and drug in this class, from dosing all the way to pertinent resistance mechanisms. You will not want to miss out on this one! This podcast was supported by an unrestricted grant from Paratek Pharmaceuticals Inc. References: Omadacycline for Mycobacterium abscessus full case series data set: 10.1128/aac.00824-23 Long term safety of omadacycline in Mycobacterium abscessus: 10.1093/ofid/ofad335 USCAST Acinetobacter baumannii Recommendations for Susceptibility Test Interpretive Criteria: https://www.uscast.org/uploads/1/1/9/0/119044870/uscast_alepak_acbc_stic_08feb23.pdf

Dr. Yohei Doi, a leading expert in antimicrobial resistance from the University of Pittsburgh, and Dr. Emily Heil, a professor and antimicrobial stewardship coordinator at the University of Maryland, discuss the complexities of treating Acinetobacter baumannii, particularly its carbapenem-resistant form (CRAB). They highlight innovative treatment options, including promising drug combinations, and delve into the challenges faced in clinical practice. Real-world experiences and research insights offer listeners a nuanced understanding of this formidable pathogen.

Experts in infectious diseases and UTIs discuss challenges in diagnosis, urine analysis nuances, white blood cell thresholds, 'pill in the pocket' strategy, evolving landscape of uncomplicated vs. complicated UTIs, new antibiotics, and diagnostic uncertainties in UTI treatment.

In this lively discussion, Dr. Emily Heil, a leading infectious diseases specialist, and Mandee Noval, a presenter of ID literature, unveil the latest advancements in infectious diseases from MAD-ID 2024. They delve into ventilator-associated pneumonia prevention studies and the complexities of antibiotic stewardship. Highlights include findings on MRSA treatment interactions and novel STI prophylaxis with doxycycline. The duo also celebrates new UK regulations on antibiotic usage, urging thoughtful practices in the field.

Join Trisha Peel, Michael Calderwood, and Patch Dellinger in a lively discussion on perioperative antibiotic management and surgical site infection prevention. Delve into controversies like post-op antimicrobial prophylaxis duration, vancomycin use, and pre-op cefazolin for penicillin-allergic patients. Learn about the importance of judicious antibiotic use in optimizing patient care and collaboration between surgery and antimicrobial stewardship for better outcomes.

In this episode, Drs. Helen Boucher (@hboucher3), Ramy Elshaboury, and Mike Dudley (@MikeMNDudley) join host, Megan Klatt (@MeganKlatt3), to discuss barriers to antimicrobial drug development, potential incentives and legislation to promote market growth, and what we can do to ensure the antimicrobial pipeline doesn’t run dry. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References An analysis of antibacterial drug development trends in the United States, 1980-2019: Dheman N, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4444-e4450. doi:10.1093/cid/ciaa859. PMID: 32584952. Antibacterial R&D at a crossroads: we’ve pushed as hard as we can…now we need to start pulling!: Rex JH, Outterson K. Clin Infect Dis. 2021 Dec 6;73(11):e4451-4453. doi:10.1093/cid/ciaa852. PMID: 32584949. No Patient Left Behind (website): https://www.nopatientleftbehind.org/ (many useful explainers of how the investment, innovation cycle, and drug pricing work) ISPOR special task force report on defining elements of value in health care – a health economics approach: Lakdawalla DN, et al. Value Health. 2018 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007. PMID: 29477390. Generalized cost-effectiveness analysis to assess treatment value in hepatitis C: Chou JW, et al. Am J Manag Care. 2023 Dec;29(12):696-703. doi: 10.37765/ajmc.2023.89468. PMID: 38170486.